During the item generation and discussion and clarification phases, the experts identified 14 distinct challenges: costs, supply challenges, lack of evidence, polypharmacy, barriers to prescription, lack of knowledge, adherence concerns, aversion to injection therapy, clinical inertia, titration needs, perceived health state, fear of adverse effects, lack of clinical guideline recommendations, and lack of measurable outcomes to guide therapy
However, the effects of these drugs on adverse limb outcomes were poorly examined
Licensed Medical Professionals Our team at Regenestem Medical Clinic includes board-certified physicians and nurse practitioners with extensive experience in weight management and metabolic health
Knowing what to say when requesting GLP-1 options from healthcare providers can help navigate these conversations more effectively
The SURPASS clinical program did not report Grade 3 or 4 injection site reactions as a primary endpoint, but post-marketing pharmacovigilance data submitted to the FDA MedWatch database include case reports of angioedema requiring emergency treatment